doi: 10.1093/humrep/den195 63
Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular uterine bleeding associated with uterine leiomyoma
Lilly also agreed to pay Chugai up to $390 million in potential payments tied to achieving milestones
Back to Journals Integrated Pharmacy Research and Practice Volume 14 Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity Authors Alzahrani AM, Alshobragi GA, Alshehri AM, Alzahrani MS, Alshehri HA, Alzhrani RM, Basudan S, Alkatheeri AA, Almutairi SA, Alzahrani YA Received 12 November 2024 Accepted for publication 13 March 2025 Published 6 April 2025 Volume 2025:14 Pages 5972 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Walid Al-Qerem Abdullah M Alzahrani, 1 3 Ghada A Alshobragi, 1 Abdullah M Alshehri, 1 Majed S Alzahrani, 1 Hasan A Alshehri, 1 Rami M Alzhrani, 4 Samah Basudan, 5 Ayed A Alkatheeri, 6 Salman A Almutairi, 7 Yahya A Alzahrani 2, 6 1 Pharmaceutical Care Department, Ministry of National GuardHealth Affairs, Jeddah, 22384, Saudi Arabia
Bowel obstructions were reported in 0.8% of Saxenda users, versus 0.17% for Contrave
